Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicentre retrospective study
Por:
Torres, T, Sood, S, Yilmaz, O, Vender, RB, Prajapati, V, Puig, L, Megna, M, Marzano, AV, Gisondi, P, Carrascosa, JM, Dauden, E, Llamas-Velasco, M, Balato, A, Leal, BG, Prignano, F, Bellinato, F, Silvi, G, Di Brizzi, E, Potestio, L, Sechi, A, Carrera, CG, López-Ferrer, A, Del-Alcazar, E, Mufti, A, Maul, LV, Piaserico, S, Maul, JT and Yeung, J
Publicada:
1 dic 2025
Ahead of Print:
1 sep 2025
Resumen:
Tildrakizumab is a monoclonal antibody targeting interleukin-23 that has gained regulatory approval for moderate-to-severe plaque psoriasis in several jurisdictions. While phase III clinical trials have evaluated its short-term efficacy and safety, real-world evidence regarding its long-term retention is limited. We report real-world drug survival of tildrakizumab in the routine clinical setting.
Filiaciones:
Torres, T:
Santo Antonio Cent Hosp, Dept Dermatol, Porto, Portugal
Univ Porto, Inst Biomed Sci Abel Salazar, Porto, Portugal
Leal, BG:
Univ Porto, Inst Biomed Sci Abel Salazar, Porto, Portugal
|